Thoruprichter2030

Functional cartilage tissue engineering needs a substantial, easy to handle scaffold with proper mechanical strength to repair defected area in articular cartilage. In this study, we report the development and characterization of demineralized bone matrix (DBM) in with a poly vinyl alcohol (PVA) to have a proper homogenous injectable scaffold. Injectabiliy of the biodegradable scaffolds, degradation rate, swelling ratio compression and tensile mechanical properties, and viability and proliferation of bone marrow mesenchymal stem cells (BM-MSCs) followed by differentiation of them In-vitro and In-vivo seeded within the scaffold were studied. It demonstrated that the PVA 20% could increase significantly (p  less then  0.05) the biodegradability of DBM after 720 hours.DBM with 20% of PVA scaffold has significantly higher (p  less then  0.05) compression and tensile mechanical strength and viscosity. SEM images showed a multilayer of cells on DBM scaffold incorporated with PVA 20%.BM-MSCs on scaffolds, DBM+PVA 20% had a significant growth rate (p  less then  0.0001) compare to 2D and low concentration of PVA after 21 days of culture. check details Viability of cells was significantly higher (p  less then  0.05) on DBM+PVA scaffold compare to DBM. DBM+PVA 20% enhanced cell viability (P  less then  0.05) compare to DBM scaffold. The PVA presence enhanced chondrogenesis differentiation at the cellular and molecular levels, as evidenced by increased COL II (P  less then  0.05) and SOX2 upregulation of Chondrogensis-specific genes (p  less then  0.001). Hyline-like cartilage covered the defect which was confirmed by microscopy and histology assessments. Having considered percentages of PVA with a constant amount of DBM, injectability, compressive mechanical properties, homogeneity of the scaffold, and providing sufficient surface area (12.25 cm2/ml) for cell attachment; 0.35 g/ml of DBM in 20% PVA (w/v) has applicable properties within the ranges of studies which can be proposed for the injectable engineered articular cartilage.HIV-1 causes millions of deaths around the world. Higher disease progression and mortality are seen in HIV positive individuals with comorbidities. Two of the most pertinent conditions are coinfection with Mycobacterium tuberculosis and Intravenous Drug abuse. The mechanisms involved, however, still remain unresolved. To elucidate the mechanisms involved, we evaluated the genetic alterations in terms of additional nuclear factor kappa B (NF-κB) sites in the long terminal repeat (LTR) of HIV-1 subtype-C isolates from infected human individuals from North India, supposedly acquired by the emerging viral quasi-species in the infected host in presence of these two comorbid conditions. Interestingly the results indicate higher number of NF-κB sites in the viral isolates from HIV-tuberculosis coinfected (n = 26, 16 isolates with 3 sites and 10 isolates with 2 sites) and intravenous drug users (n = 20, 13 isolates with 3 sites and 7 isolates with 2 sites) compared to the mono-infected hosts (n = 30, 10 isolates with 3 sites, 18 isolates with 2 sites, 2 isolates with 1 site). The biological relevance of these alterations in the NF-κB sites within the HIV-1 LTR with respect to viral replicative capacity and HIV disease progression needs to be studied further.

Picture My Participation (PmP) is a promising instrument for measuring the participation in everyday situations of children with intellectual disability (ID), particularly in low- and middle-income countries.

To explore test-retest reliability of PmP by comparing two repeated measurements of children with ID in an urban context in South Africa.

A picture-supported interview with 31 children with ID, aged 7-17 years, was conducted twice, two weeks apart. The children rated their participation, operationalised as attendance and involvement, in 20 everyday activities. Analyses were completed for total scores, for the four subcomponents and at item level.

Test-retest agreement at an item level for both attendance and involvement showed slight/fair agreement for most activities (Kappa = 0.01-0.40), and moderate agreement for some activities (Kappa = 0.41-0.60). Moderate agreement was shown for the total scale and at component level (ICC = 0.5-0.75), except for (firstly) attendance of and involvement in 'Family Activities' (ICC = 0.26 for attendance, 0.33 for involvement), and (secondly) involvement in 'Personal Activities' (ICC = 0.33).

The result indicates that PmP can reliably be used at component level and as a screening tool for intervention planning to identify participation and participation restrictions in children with ID.

The result indicates that PmP can reliably be used at component level and as a screening tool for intervention planning to identify participation and participation restrictions in children with ID.

To analyse the frequency and characteristics of the Janus kinase 2 (

V617F mutation in patients with cerebral venous sinus thrombosis (CVST) with thrombocytosis.

The study enrolled CVST patients with thrombocytosis that had undergone

V617F mutation detection to determine the frequency of the

V617F mutation in this cohort. Correlations between patient demographics, whole blood cell counts, targeted sequencing results and

V617F mutation status were determined.

A total of 23 patients were enrolled in the study 11 (47.8%) with the

V617F mutation and 12 (52.2%) without the

V617F mutation. The mean platelet count was significantly higher in patients with the

V617F mutation than in patients without the mutation (478.1 ± 107.4 × 10

/l versus 374.4 ± 54.1 × 10

/l, respectively). There were no significant differences in age, sex, white blood cell count or haemoglobin level between the two groups. Other than single nucleotide polymorphisms, no hot-spot mutations associated with myeloid tumours other than the

V617F mutation were detected in four CVST patients that underwent targeted sequencing.

The

V617F mutation was frequently detected in CVST patients with thrombocytosis and it was associated with higher platelet counts.

The JAK2 V617F mutation was frequently detected in CVST patients with thrombocytosis and it was associated with higher platelet counts.